[PDF] Top 20 The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial
Has 10000 "The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial" found on our website. Below are the top 20 most common "The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial".
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial
... supported in part by grants from the Kay Kend- all Foundation, the Leukemia Cooperative Group of the EORTC and the National Cancer Institute (grant numbers 5U10 ... Voir le document complet
8
Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <= 50 years old in first complete remission: results of the EORTC ALL-3 trial
... Patients with initial low WBC (< 30 × 10 9 /L) had a sig- nificantly ...those with a WBC ≥ 30 × 10 9 /L: the hazard ratio was ...and the 6-year DFS rate was 45.3% (± ... Voir le document complet
9
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
... is the absence of a significant differ- ence at 2 years, in terms of NRM, which was quite low in both groups ...to the retrospective nature of the study, we could ... Voir le document complet
11
Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia
... secondary acute myeloid leukemia (sAML), occurring after antecedent hematologic diseases, previous chemotherapy or radiation, has an inferior prognosis compared with de novo ...define ... Voir le document complet
10
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.
... Outcomes in Patients ≤ 60 Years Old with Secondary Acute Myeloid Leukemia (s-AML) Occurring after MDS or Other Malignancies ...Outcomes The baseline characteristics ... Voir le document complet
15
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
... Although the overall survival (OS) in younger acute myeloid leukemia (AML) patients has improved in the recent decades, disease relapse remains ... Voir le document complet
11
The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party
... represent the most frequent stem cell source for allo-SCT in Europe and are used in more than 50 % of RIC allo-SCT for AML patients ...[15]. In the ... Voir le document complet
15
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
... The introduction of the BCR-ABL–directed tyrosine kinase inhibitors (TKIs) to the front-line therapy for Ph- positive ALL has improved CR rates, the quality of responses, and ... Voir le document complet
11
Physician Uncertainty Aversion Impacts Medical Decision Making For Older Patients With Acute Myeloid Leukemia: Results Of A National Survey
... lderly patients with acute myeloid leukemia can be treated with intensive chemotherapy, low-intensity therapy such as low-dose aracytine or hypomethylating agents, or best ... Voir le document complet
10
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT
... INTRODUCTION The introduction of reduced intensity (RIC) allogeneic stem cell transplantation into the mainstay of clinical management of older patients with ... Voir le document complet
8
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
... INTRODUCTION Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous disease characterized by accumulation of a variety of somatically acquired genetic ... Voir le document complet
10
Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation
... Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a ... Voir le document complet
4
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3internal tandem duplication: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
... associated with better outcomes, including better CIR, LFS, OS and ...therapy with sorafenib significantly reduced the CIR and improved LFS, OS and ...by the type of donor or ... Voir le document complet
10
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission
... support the theory that in AML patients in CR1, the graft-versus-leukemia effect provided by the allograft can eliminate residual disease in long-term survi- ... Voir le document complet
7
Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?
... study of prophylactic DLI in patients with high-risk acute leukemia has been reported by Liga et ...ago. In that study, patients were given allo-HCT ... Voir le document complet
3
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC
... remains the most important factor predicting survival for patients in our ...keeping in mind that CR1 and CR2 cases achieved similar survivals ...highlights the potential impact ... Voir le document complet
11
Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples.
... (for the Training Set only). Briefly, the Invar- iant Rank normalization method was applied to the primary probe data obtained from the Training Set sam- ...to the following criteria: ... Voir le document complet
13
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT
... higher risk of relapse, while those transplanted with ac- tive disease had increased RI and ...effect of allo-SCT with higher relapse rates in ALL in ... Voir le document complet
13
Transmission of chronic myeloid leukemia through peripheral-blood stem-cell transplantation.
... The results of bone marrow evaluation on day 100 were normal, with more than 95 percent chi- merism, but the karyotype showed a Philadelphia chromosome in 9 of 31 ... Voir le document complet
2
Dexamethasone in hyperleukocytic acute myeloid leukemia
... enrichment in the dexamethasone Figure 4. Activity of dexamethasone against acute myeloid leukemia ...effect of dexamethasone on AML cell lines cultured ... Voir le document complet
12
Sujets connexes